Diagnostic Utility of Direct Immunofluorescence in Non-Diabetic Kidney Diseases Among Type II Diabetic Patients

Background: Diabetic Nephropathy (DN) is the leading cause of end-stage kidney disease (ESKD) globally and a major microvascular complication of diabetes. However, Non-Diabetic Kidney Disease (NDKD), including glomerular (e.g., membranous nephropathy, IgAnephropathy), tubulointerstitial, and vascular diseases, either in isolation or in combination with Diabetic Nephropathy (DN) in patients with diabetes. Recent reports indicate an increasing prevalence of NDKD in diabetics, likely due to aging, infections, monoclonal gammopathies, and malignancies. Timely diagnosis of NDKD is critical, as early treatment may halt, reverse, or significantly slow progression to CKD or ESKD. Type 2 DM patients are more commonly affected by NDKD than those with Type 1 DM. While clinical and biochemical parameters may raise suspicion for NDKD, kidney biopsy with Direct Immunofluorescence (DIF) remains the gold standard for distinguishing DN from NDKD. DIF plays a crucial role in identifying immune-complex mediated glomerulopathies that might be missed on light microscopy alone, guiding therapeutic decisions and influencing prognosis. Accurate biopsy interpretation demands thorough understanding of renal pathology, correlating clinical, laboratory, light microscopy, and immunofluorescence findings. Aim: To study the histopathological spectrum of non-diabetic kidney diseases (NDKD) in patients with Type II Diabetes Mellitus using immunofluorescence, and to correlate the clinical presentation and laboratory findings with the histopathological diagnosis. Study Design: A prospective, observational study conducted over 1.5 years (January 2023–June 2024) at MGM Medical College and Hospital, Navi Mumbai. The study included 50 ultrasound-guided renal biopsies from patients diagnosed with Type II Diabetes Mellitus, selected based on clinical suspicion of NDKD. Result: A total of 50 cases were studied, comprising 19 cases of isolated NDRD, 17 cases of combined NDRD with Diabetic Nephropathy (NDRD+DN), and 14 cases of isolated Diabetic Nephropathy (DN). The peak incidence was observed in the 40–60-year age group. Of the 50 patients, 39 (78%) were males and 11 (22%) were females, yielding a male-to-female ratio of 3.5:1, indicating male predominance. A significant association was noted between longer duration of diabetes and higher HbA1c levels with cases of isolated DN. Among the NDRD and NDRD+DN groups, the most common histopathological lesions identified were Acute Tubular Injury (ATI) and Acute Pyelonephritis (APN), possibly reflecting changing epidemiological trends, increasing age, infections, and malignancy risk in this population. Direct Immunofluorescence (DIF) proved indispensable for diagnosing immune complex glomerulopathies. While Linear IgG deposits along the glomerular basement membrane confirmed DN, granular deposits of IgA, IgM, C3, and C1q were diagnostic of NDRD subtypes such as IgA Nephropathy, Membranoproliferative Glomerulonephritis (MPGN), and Post-Infectious Glomerulonephritis (PIGN). Conclusion: It is imperative to evaluate diabetic patients—especially those with a shorter duration of diabetes or lower HbA1c—who present with sudden-onset proteinuria, an acute rise in serum creatinine, or atypical urinary findings. Early renal biopsy in such cases facilitates timely diagnosis and management of NDRD. Accurate histopathological diagnosis, supplemented by DIF, is crucial for initiating timely and specific treatment, which may prevent progression to chronic kidney disease or end-stage kidney disease. By enhancing diagnostic accuracy, DIF helps optimize clinical outcomes, prevents under diagnosis or misdiagnosis of NDRD, and underscores the need for its routine inclusion in renal biopsy analysis for diabetics with atypical presentations.